SHAREHOLDERS' EQUITY (Tables)
 12 Months Ended
Dec. 31, 2021
Stockholders' Equity Note [Abstract]  
Composition of Shares Capital
   
Year ended December 31,
  
   
2021
    
2020
    
2019
  
                   
Cost of revenues
  
$
 15,462    
$
 9,127    
$
 5,854  
Research and development
     70,020       76,883       56,161  
Selling and marketing
     33,853       22,845       18,458  
General and administrative
     102,056       38,458       28,864  
                         
Total share-based compensation expense
  
$
 221,391    
$
 147,313    
$
 109,337  
Schedule of Stock Options Granted to Employees Activity
   
Number
of
options
    
Weighted
average
exercise
price
    
Weighted
Average
remaining contractual term
(in years)
    
Aggregate
intrinsic value
  
                         
Balance at December 31, 2020
     4,618,380    
$
 74.31       6.74    
$
 812,500  
                                 
Granted
     712,485       250.71                  
Exercised
     (531,788
)
     62.87                  
Forfeited
     (81,877
)
     107.62                  
                                 
Balance at December 31, 2021
     4,717,200       101.66       6.32       339,012  
                                 
Exercisable at December 31, 2021
     3,213,149       65.72       5.39       305,280  
                                 
Vested and expected to vest at December 31, 2021
     4,647,663    
$
 100.60       6.29    
$
 337,290  
Schedule of Stock Option Valuation Assumptions - Compensation to Employees
   
Year ended December 31,
   
2021
  
2020
  
2019
             
Expected volatility
  
48.91%-52.22%
  
42.26%-49.24%
  
42.60%-45.24%
Expected dividends
  
0%
  
0%
  
0%
Expected term (in years)
  
4.85-4.91
  
4.84-4.99
  
4.94-4.99
Risk free rate
  
0.44%-1.22%
  
0.25%-1.40%
  
1.51%-2.47%
 
   
Year ended December 31,
   
2021
  
2020
  
2019
             
Expected volatility
  
56.94%-59.23%
  
34.52%-83.3%
  
31.88%-54.49%
Expected dividends
   0%   0%   0%
Expected term (in years)
   0.5   0.5   0.5
Risk free rate
  
0.06%-0.07%
  
0.13%-0.95%
  
1.89%-2.52%
Summary of Options Data
   
Year ended December 31,
  
   
2021
    
2020
    
2019
  
                   
Weighted-average grant date fair value of options granted, per optionz
  
$
127.36
    
$
68.91
    
$
53.67
  
Total intrinsic value of the options exercised
  
$
 114,113    
$
 436,187    
$
 128,003  
Total fair value of shares vested
  
$
 49,045    
$
 40,367    
$
 33,316  
Schedule of Options Outstanding and Exercisable
Exercise price
(range)
    
Options outstanding
as of
December 31, 2021
    
Weighted average remaining
contractual term
    
Options exercisable
as of December 31,
2021
    
Weighted average remaining
contractual term
  
           
(years)
          
(years)
  
                           
0-19.79
       364,941       2.19       357,975       2.07  
19.8-21.13
       563,467       3.71       563,467       3.71  
21.14-51.32
       243,431       4.08       238,431       4.06  
51.33-56.61
       398,038       5.12       398,038       5.12  
56.62-61.75
       648,082       6.12       579,583       6.12  
61.76-101.67
       332,623       6.57       242,169       6.43  
101.68-102.67
       603,279       7.12       380,074       7.12  
102.68-142.09
       237,781       7.59       137,373       7.48  
142.1-143.13
       520,670       8.14       214,450       8.14  
143.14-353.09
       804,888       9.18       101,589       8.83  
                                   
        4,717,200       6.32       3,213,149       5.39  
Schedule Stock Options Outstanding and Exercisable to Non-Employees
Grant
Date
  
Options outstanding
as of
December 31, 2021
    
Exercise price
    
Exercisable
as of December 31,
2021
  
Exercisable through
                     
January 9, 2013
     3,400    
$
 2.34       3,400  
January 9, 2023
Schedule of Restricted Stock Unit Activity
   
Number
of
shares
    
Weighted
average
grant date
fair value per share
  
             
Unvested as of December 31, 2020
     2,078,427    
$
 150.87  
                 
Granted
     1,303,693    
 
 243.47  
Vested
     (935,912
)
  
 
 139.15  
Forfeited
     (220,759
)
  
 
 196.20  
                 
Unvested as of December 31, 2021
     2,225,449    
$
 205.31  
Schedule of Total Accumulated Other Comprehensive Loss, Net
   
Year ended December 31, 2021
  
   
Marketable securities
    

Cash flow
hedges

    
Total
  
                   
Beginning balance, net
  
$
 3,768    
$
 5,638    
$
 9,406  
Other comprehensive income before reclassifications, net
     (4,672
)
     119       (4,553
)
Amounts reclassified from accumulated other comprehensive income to earnings:
                        
Cost of revenues
     -       (279
)
     (279
)
Research and development, net
     -       (3,644
)
     (3,644
)
Selling and marketing
     -       (1,217
)
     (1,217
)
General and administrative
     -       (740
)
     (740
)
Financial income (expenses), net
     (29
)
     -       (29
)
                         
Total accumulated other comprehensive income, net
  
$
 (933
)
  
$
 (123
)
  
$
 (1,056
)
   
Year ended December 31, 2020
  
   

Marketable
securities

    

Cash flow
hedges

    
Total
  
                   
Beginning balance, net
  
$
 852    
$
 505    
$
 1,357  
Other comprehensive income before reclassifications, net
     2,962       11,425       14,387  
Amounts reclassified from accumulated other comprehensive income to earnings:
                        
Cost of revenues
     -       (269
)
     (269
)
Research and development, net
     -       (3,995
)
     (3,995
)
Selling and marketing
     -       (1,300
)
     (1,300
)
General and administrative
     -       (728
)
     (728
)
Financial income (expenses), net
     (46
)
     -       (46
)
                         
Total accumulated other comprehensive income, net
  
$
 3,768    
$
 5,638    
$
 9,406